6 results on '"Eduardo Dávila-González"'
Search Results
2. Case Report: Extrapulmonary Manifestations of COVID-19 and Dengue Coinfection
- Author
-
Leticia Rivas-Tovar, Rosa M. del Angel, Crescencio González-González, Fernando Bastida-González, Paola Zárate-Segura, María J. Pérez-Méndez, Eduardo Dávila-González, José Manuel Reyes-Ruiz, Aarón P Gutiérrez-Garduño, Enrique Villegas-del Angel, Juan Fidel Osuna-Ramos, Luis Adrián De Jesús-González, Rosa Campuzano-Vences, and Carlos Noe Farfan-Morales
- Subjects
myalgia ,medicine.medical_specialty ,Erythema ,business.industry ,virus diseases ,Dengue virus ,medicine.disease ,Chest pain ,medicine.disease_cause ,Gastroenterology ,Dengue fever ,Diarrhea ,Infectious Diseases ,Virology ,Internal medicine ,medicine ,Coinfection ,Parasitology ,Clinical Case Report ,medicine.symptom ,business ,Odynophagia - Abstract
The risk of coronavirus disease 2019 (COVID-19) and dengue coinfection is increased in tropical countries; however, the extrapulmonary clinical manifestations have not been fully characterized. We report a 42-year-old woman whose clinical manifestations began with fever, diarrhea, headache, chest pain, myalgia, odynophagia, and arthralgia. Despite mild respiratory symptoms and normal chest computed tomography scan results, she was diagnosed with real-time reverse-transcription polymerase chain reaction (RT-PCR)-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Because she had erythema and petechiae with a decreased platelet count, the dengue NS1 antigen and anti-dengue IgM/IgG test were performed, and the Centers for Disease Control and Prevention RT-PCR assay detected the dengue virus serotype 1 infection. Additionally, increased liver enzyme serum levels were found in the patient, who later developed hepatomegaly. Hence, the mechanism of hepatic pathology associated with SARS-CoV-2 and dengue coinfection needs further research.
- Published
- 2021
3. Association of GSTT1, GSTM1 and GSTP1 (Ile105Val) mRNA Expression with Cardiometabolic Risk Parameters in Women with Breast Cancer and Comorbidities
- Author
-
Yizel Becerril Alarcón, Fernando Bastida González, Isidro Roberto Camacho Beiza, Eduardo Dávila González, José Alfonso Cruz Ramos, Alejandra Donají Benítez Arciniega, Roxana Valdés Ramos, and Alexandra Estela Soto Piña
- Subjects
General Earth and Planetary Sciences ,General Environmental Science ,Glutathione S-transferase genotypes ,cardiometabolic risk ,breast cancer ,comorbidities - Abstract
Breast cancer (BC) and cardiometabolic diseases share a multifactorial and modifiable etiology, modulated by complex molecular pathways. Glutathione S-transferase (GST) plays a critical role, providing protection against xenobiotics and regulating levels of enzymes and proteins in the cell. GST variants have a significant impact on susceptibility to diseases whose pathogenesis involves oxidative stress, as is the case in many inflammatory diseases such as BC and cardiometabolic pathologies. However, the expression of these polymorphic variants has not been studied in BC. This study aimed to evaluate the presence of GST mRNA isoforms and their association with clinical and cardiometabolic parameters in women with BC. This was a case-control study, and a total of 57 participants were recruited. Concentrations of glucose and lipids in blood were measured in all the participants. GST variants (GSTT1, GSTM1 and GSTP1 Ile105Val polymorphism) were evaluated in all the participants by real-time PCR analysis. There was a significant association (p < 0.05) between the frequency of GSTP1 and LDL-c in the BC group. However, the control group showed significant associations between blood pressure with GSTT1 and GSTP1 variants with total cholesterol (TC), LDL-c, VLDL-c and triacylglycerols (TG). Therefore, GSTT1 and GSTP1 variants could be emerging biomarkers to discriminate between BC cases related or not to cardiometabolic disease factors.
- Published
- 2022
- Full Text
- View/download PDF
4. A case report of newborn infant with severe COVID-19 in Mexico: Detection of SARS-CoV-2 in human breast milk and stool
- Author
-
Eduardo Dávila-González, María J. Pérez-Méndez, Paloma V. Bobadilla-Montes de Oca, José Manuel Reyes-Ruiz, Paola Zárate-Segura, Lidia E. García-Sosa, Alejandro Hinojosa-Velasco, Jaime García-Mena, Dolores G. Ramírez-Hernández, J. Gabriel Mendoza-Durán, and Fernando Bastida-González
- Subjects
0301 basic medicine ,Microbiology (medical) ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,viruses ,030106 microbiology ,Case Report ,medicine.disease_cause ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,0302 clinical medicine ,Neonate ,medicine ,Viral rna ,lcsh:RC109-216 ,030212 general & internal medicine ,skin and connective tissue diseases ,Human breast milk ,Coronavirus ,Transmission (medicine) ,business.industry ,SARS-CoV-2 ,fungi ,Human milk ,COVID-19 ,General Medicine ,Virology ,Infant newborn ,respiratory tract diseases ,body regions ,Infectious Diseases ,Vertical transmission ,business - Abstract
Highlights • The first published case of newborn infant SARS-CoV-2 infection in Mexico. • SARS-CoV-2 RNA is detected in Human Breast Milk and Stool. • The intrauterine infection and breastfeeding could be mechanisms for vertical transmission of SARS-CoV-2., Although COVID-19 in pregnant women and their neonates has been demonstrated, there is not enough evidence about how this vertical transmission occurs. This report describes a SARS-CoV-2 infection in a 21-year-old mother-daughter duo at the time of birth, focusing on the viral RNA detection in the stool of both and the human breast milk.
- Published
- 2020
5. The Entero-Mammary Pathway and Perinatal Transmission of Gut Microbiota and SARS-CoV-2
- Author
-
Carmen Josefina Juárez-Castelán, Juan Manuel Vélez-Ixta, Karina Corona-Cervantes, Alberto Piña-Escobedo, Yair Cruz-Narváez, Alejandro Hinojosa-Velasco, María Esther Landero-Montes-de-Oca, Eduardo Davila-Gonzalez, Eduardo González-del-Olmo, Fernando Bastida-Gonzalez, Paola Berenice Zárate-Segura, and Jaime García-Mena
- Subjects
SARS-CoV-2 ,mother rectal swab ,neonate rectal swab ,human colostrum ,high-throughput DNA sequencing ,fecal microbiota ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
COVID-19 is a severe respiratory disease threatening pregnant women, which increases the possibility of adverse pregnancy outcomes. Several recent studies have demonstrated the ability of SARS-CoV-2 to infect the mother enterocytes, disturbing the gut microbiota diversity. The aim of this study was to characterize the entero-mammary microbiota of women in the presence of the virus during delivery. Fifty mother–neonate pairs were included in a transversal descriptive work. The presence of SARS-CoV-2 RNA was detected in nasopharyngeal, mother rectal swabs (MRS) and neonate rectal swabs (NRS) collected from the pairs, and human colostrum (HC) samples collected from mothers. The microbiota diversity was characterized by high-throughput DNA sequencing of V3-16S rRNA gene libraries prepared from HC, MRS, and NRS. Data were analyzed with QIIME2 and R. Our results indicate that several bacterial taxa are highly abundant in MRS positive for SARS-CoV-2 RNA. These bacteria mostly belong to the Firmicutes phylum; for instance, the families Bifidobacteriaceae, Oscillospiraceae, and Microbacteriaceae have been previously associated with anti-inflammatory effects, which could explain the capability of women to overcome the infection. All samples, both positive and negative for SARS-CoV-2, featured a high abundance of the Firmicutes phylum. Further data analysis showed that nearly 20% of the bacterial diversity found in HC was also identified in MRS. Spearman correlation analysis highlighted that some genera of the Proteobacteria and Actinobacteria phyla were negatively correlated with MRS and NRS (p < 0.005). This study provides new insights into the gut microbiota of pregnant women and their potential association with a better outcome during SARS-CoV-2 infection.
- Published
- 2022
- Full Text
- View/download PDF
6. Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro
- Author
-
Mónica Salas Rojas, Raúl Silva Garcia, Estela Bini, Verónica Pérez de la Cruz, Juan Carlos León Contreras, Rogelio Hernández Pando, Fernando Bastida Gonzalez, Eduardo Davila-Gonzalez, Mario Orozco Morales, Armando Gamboa Domínguez, Julio Sotelo, and Benjamín Pineda
- Subjects
SARS CoV-2 ,quinacrine ,antiviral drugs ,virus replication ,Microbiology ,QR1-502 - Abstract
Quinacrine (Qx), a molecule used as an antimalarial, has shown anticancer, antiprion, and antiviral activity. The most relevant antiviral activities of Qx are related to its ability to raise pH in acidic organelles, diminishing viral enzymatic activity for viral cell entry, and its ability to bind to viral DNA and RNA. Moreover, Qx has been used as an immunomodulator in cutaneous lupus erythematosus and various rheumatological diseases, by inhibiting phospholipase A2 modulating the Th1/Th2 response. The aim of this study was to evaluate the potential antiviral effect of Qx against denominated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Vero E6 cells. The cytotoxicity of Qx in Vero E6 cells was determined by the MTT assay. Afterwards, Vero E6 cells were infected with SARS-CoV-2 at different multiplicities of infections (MOIs) of 0.1 and 0.01 in the presence of Qx (0–30 µM) to determinate the half maximal effective concentration (EC50). After 48 h, the effect of Qx against SARS-CoV-2 was assessed by viral cytotoxicity and viral copy numbers, the last were determined by digital real-time RT-PCR (ddRT-PCR). Additionally, electron and confocal microscopy of Vero E6 cells infected and treated with Qx was studied. Our data show that Qx reduces SARS-CoV-2 virus replication and virus cytotoxicity, apparently by inhibition of viral ensemble, as observed by ultrastructural images, suggesting that Qx could be a potential drug for further clinical studies against coronavirus disease 2019 (COVID-19) infection.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.